Tibotec Prezista Mortality Imbalance Due To Partially Blinded Trials – FDA Review
This article was originally published in Pharmaceutical Approvals Monthly
FDA officials called the lack of deaths in the control arms of Tibotec’s Prezista trials "striking" and "out of the range of past experience," and attributed the anomaly to the partially blinded study design.
You may also be interested in...
The increased incidence of bacterial pneumonia seen with Roche/Trimeris’ Fuzeon may be an artifact of the design of the pivotal trails, FDA suggested in review documents for the HIV therapy.
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011